Blar i Bergen Open Research Archive på forfatter "Mori, Amani Thomas"
-
Budget impact analysis of using dihydroartemisinin–piperaquine to treat uncomplicated malaria in children in Tanzania
Mori, Amani Thomas; Norheim, Ole Frithjof; Robbestad, Bjarne (Peer reviewed; Journal article, 2016-03)Background and Objective: Dihydroartemisinin–piperaquine (DhP) is a very cost effective anti-malarial drug. The aim of this study was to predict the budget impact of using DhP as a first- or second-line drug to treat ... -
Cost-benefit and extended cost-effectiveness analysis of a comprehensive adolescent pregnancy prevention program in Zambia: study protocol for a cluster randomized controlled trial
Mori, Amani Thomas; Kampata, Linda Milimo; Musonda, Patrick; Johansson, Kjell Arne; Robberstad, Bjarne; Sandøy, Ingvild Fossgard (Peer reviewed; Journal article, 2017-12-19)Background: Early marriages, pregnancies and births are the major cause of school drop-out among adolescent girls in sub-Saharan Africa. Birth complications are also one of the leading causes of death among adolescent ... -
Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania
Mori, Amani Thomas; Ngalesoni, Frida; Norheim, Ole Frithjof; Robberstad, Bjarne (Peer reviewed; Journal article, 2014-09-15)Background: Dihydroartemisinin-piperaquine (DhP) is highly recommended for the treatment of uncomplicated malaria. This study aims to compare the costs, health benefits and cost-effectiveness of DhP and artemether-lumefantrine ... -
The cost-effectiveness of incentive-based active case finding for tuberculosis (TB) control in the private sector Karachi, Pakistan
Hussain, Hamidah; Mori, Amani Thomas; Khan, Aamir Javed; Khowaja, Saira; Creswel, Jacob; Tylleskär, Thorkild; Robberstad, Bjarne (Peer reviewed; Journal article, 2019-10-12)Background: In Asia, over 50% of patients with symptoms of tuberculosis (TB) access health care from private providers. These patients are usually not notified to the National TB Control Programs, which contributes to low ... -
Equity impact analysis of medical approaches to cardiovascular diseases prevention in Tanzania
Ngalesoni, Frida Namnyak; Ruhago, Georg Mugambage; Mori, Amani Thomas; Robberstad, Bjarne; Norheim, Ole Frithjof (Peer reviewed; Journal article, 2016-12)Primary medical prevention of cardiovascular disease (CVD) has received low priority in Tanzania, despite evidence of the rising prevalence of CVD risk factors. Different guidelines have been proposed for medical CVD ... -
Implementing standard antenatal care interventions: health system cost at primary health facilities in Tanzania
Chamani, Amisa Tindamanyile; Mori, Amani Thomas; Robberstad, Bjarne (Journal article; Peer reviewed, 2021)Background Since 2002, Tanzania has been implementing the focused Antenatal Care (ANC) model that recommended four antenatal care visits. In 2016, the World Health Organization (WHO) reintroduced the standard ANC model ... -
Patient and health system costs of managing pregnancy and birth-related complications in sub-Saharan Africa: a systematic review
Mori, Amani Thomas; Binyaruka, Peter; Hangoma, Peter; Robberstad, Bjarne; Sandøy, Ingvild Fossgard (Journal article; Peer reviewed, 2020)Background Morbidity and mortality due to pregnancy and childbearing are high in developing countries. This study aims to estimate patient and health system costs of managing pregnancy and birth-related complications in ... -
Pharmacoeconomics and Formulary Decision-Making in Tanzania. Generating Evidence for Antimalarial Drugs
Mori, Amani Thomas (Doctoral thesis, 2015-11-24)Introduction: Increasing expenditure on pharmaceuticals has prompted many authorities, mostly in high-income countries, to deploy pharmacoeconomic analysis as a tool to guide formulary decision-making. However, the role ... -
Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review
Mori, Amani Thomas; Robberstad, Bjarne (Peer reviewed; Journal article, 2012-09-27)Background: Due to escalating treatment costs, pharmacoeconomic analysis has been assigned a key role in the quest for increased efficiency in resource allocation for drug therapies in high-income countries. The extent to ... -
Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: evaluation against the accountability for reasonableness framework
Mori, Amani Thomas; Kaale, Eliangiringa Amos (Peer reviewed; Journal article, 2012-03-18)Background: Priority setting for artemisinin-based antimalarial drugs has become an integral part of malaria treatment policy change in malaria-endemic countries. Although these drugs are more efficacious, they are also ... -
Reforms: a quest for efficiency or an opportunity for vested interests'? a case study of pharmaceutical policy reforms in Tanzania
Mori, Amani Thomas; Kaale, Eliangiringa Amos; Risha, Peter (Peer reviewed; Journal article, 2013-07-13)Background: Regulation of the pharmaceutical sector is a challenging task for most governments in the developing countries. In Tanzania, this task falls under the Food and Drugs Authority and the Pharmacy Council. In 2010, ... -
The role of evidence in the decision-making process of selecting essential medicines in developing countries: the case of Tanzania
Mori, Amani Thomas; Kaale, Eliangiringa Amos; Ngalesoni, Frida; Norheim, Ole Frithjof; Robberstad, Bjarne (Peer reviewed; Journal article, 2014-01-08)Background: Insufficient access to essential medicines is a major health challenge in developing countries. Despite the importance of Standard Treatment Guidelines and National Essential Medicine Lists in facilitating ...